- Combined assessment of KRAS mutational status and tumor size has no 1 2 impact on prognosis in early-stage non-small cell lung cancer 3 4 5 Ella A. Eklund^{1,2,3}, Ali Mourad^{1,2}, Clotilde Wiel¹, Sama I. Sayin³, Henrik Fagman^{4,5}, 6 Andreas Hallqvist^{3,7}, Volkan I. Sayin^{1,2} 7 8 ¹Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer 9 Research, University of Gothenburg, Gothenburg, Sweden ²Wallenberg Centre for Molecular and Translational Medicine, University of 10 Gothenburg, Gothenburg, Sweden 11 12 ³Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; ⁴Department of Laboratory Medicine, Institute of Biomedicine, University of 13 14 Gothenburg, Gothenburg, Sweden 15 ⁵Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, 16 Sweden ⁶Department of Microbiology and Immunology, Institute for Biomedicine, Sahlgrenska 17 18 Academy, University of Gothenburg, Gothenburg, Sweden 19 ⁷Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden 20 21 22 23 24 25 Correspondence to: 26 volkan.sayin@gu.se 27 28 Keywords: lung cancer, KRAS, tumor size, stage I and II, clinical outcome 29 Abbreviations:¹ 30 Word count: 3024 31 Number of main figures: 4
- 32 Number of tables: 2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. CT: Computed Tomography; ECOG: Eastern Cooperative Oncology Group; HR: Hazard Ratio; NSCLC: Non-Small Cell Lung Cancer; NGS: Next Generation Sequencing; PS: Performance Status; OS: Overall Survival;

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

34 Abstract

35

36 Background: KRAS mutation status, stage and tumor size at the time of diagnosis are well-37 established independent prognostic factors in non-small cell lung cancer (NSCLC). Here, we 38 investigate the prognostic value of combining survival data on KRAS mutation status and 39 tumor size in early-stage NSCLC.

40

41 Methods: We studied the combined impact of KRAS mutational status and tumor size on 42 overall survival (OS) and risk of death in patients with stage I-II NSCLC. We performed a 43 retrospective study including 310 consecutively diagnosed patients with early (stage I-II) 44 NSCLCs. All consecutive patients molecularly assessed and diagnosed between 2016-2018 45 with stage I-II NSCLC in the Västra Götaland region of western Sweden were included in this 46 multi-center retrospective study. The primary study outcome was OS and risk of death (hazard 47 ratio).

48

49 Results: Out of 310 patients with stage I-II NSCLC, 37% harbored an activating mutation in 50 the KRAS gene. Our study confirmed staging and tumor size as prognostic factors. However, 51 KRAS mutational status was not found to impact OS and there was no difference in the risk of 52 death when combining KRAS mutational status and primary tumor size.

53

54 **Conclusions:** In our patient cohort, KRAS mutations in combination with primary tumor size 55 are not associated with a worse prognosis in stage I-II NSCLC.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

56 Introduction

57 Non-small cell lung cancer (NSCLC) is the second most common cancer worldwide with 2.1 58 million new cases annually and the highest mortality rate with 1.8 million deaths. [1] Staging 59 is a crucial aspect of NSCLC management, as it is one of the most important predictors of 60 survival. The TNM staging system describes key tumor characteristics such as size, location, 61 and whether the disease has spread to lymph nodes and/or distant organs [2-5]. There are 62 four main stages in NSCLC (stage I-IV), with stage IV having the worst prognosis. Pathological 63 stage is considered the most important prognostic factor for resected patients, with 5-year 64 survival rates, gradually decreasing across stages, of 83% for stage IA, 71% for IB, 57% for 65 IIA, 49% for IIB, 36% for IIIA, and 23% for IIIB [4].

66

67 The most frequent oncogenic driver in NSCLC is the Kirsten rat sarcoma viral oncogene 68 (KRAS), which is present in up to 40% of all cases, with the most common mutations being 69 G12C, G12V, and G12D [6]. KRAS mutations are associated with worse outcomes after 70 chemotherapy and radiotherapy, with shorter OS in stage III and IV patients [7-14]. In early-71 stage NSCLC, however, while several studies have shown that KRAS mutations negatively 72 influence the prognosis [15-17], others have shown no significant effect [18]. Most recently, it 73 was reported that KRAS G12C mutation (but not other KRAS mutations or with no mutation in 74 KRAS) significantly increased risk of disease recurrence in stage I surgically resected lung 75 adenocarcinomas [19]. However, while the study found this in two distinct local cohorts of IRE-76 LUAD (Rome, Italy) and MSK-LUAD (New York, USA), data extracted from The Cancer 77 Genome Atlas (TCGA) showed no significant difference. Hence, the debate about the 78 prognostic value of KRAS mutational status in early NSCLC is ongoing [20, 21]. In fact, given 79 the lack of consensus regarding its effects on prognosis, testing for KRAS mutations for 80 resectable stage I and II tumors is currently not recommended in clinical guidelines [22]. In 81 addition, several inhibitors that specifically bind KRAS-G12C have been investigated in clinical 82 trials, with sotorasib becoming the first treatment to gain approval for adults with stage IV 83 NSCLC harboring a KRAS-G12C mutation as second-line therapy [23-27]. However, 84 treatment with sotorasib is not currently recommended for patients with early-stage NSCLC 85 due to lack of evidence showing positive outcomes of treatment in this group.

86

87 Therefore, further investigations are warranted to identify potential subgroups in Stage I-III 88 disease who may still have to gain from effective and well-established treatments, and to add 89 to the pool of clinical data required to study this further. One strategy is to stratify patients 90 according to KRAS mutational status together with other key prognostic factors, such as tumor 91 size. Primary tumor size is an established prognostic factor in NSCLC, with larger tumors 92 being associated with poorer survival [21, 28-31]. The reason for this association is not yet 93 fully understood but larger tumors may be more resistant to therapy due to having poorer blood 94 supply, differential metabolism, and potentially a higher likelihood of micrometastatic disease 95 compared to smaller tumors [32-35]. Further research is needed to elucidate the underlying 96 mechanisms. However, when considering primary tumor size, the grouping as early (I-II), 97 advanced (III), and metastasized (IV) NSCLC can be argued to be more clinically relevant due 98 to that stage I-II is primarily based on tumor size whereas a spread to the lymph nodes, a 99 negative prognostic factor, is more common in stage III [3, 21].

100

101 To our knowledge, no one has investigated the combined impact of primary tumor size and 102 KRAS mutational status on OS and risk of death in stage I-II NSCLC. However, in Sweden, 103 reflex testing for targetable alterations in NSCLC, including KRAS mutational status, has been 104 widely implemented since 2015 for all stages. By including all consecutive patients diagnosed 105 with stage I-II NSCLC and molecularly assessed between 2016-2018 in Västra Götaland, the 106 second largest county in Sweden with a population of 1.7 million, the current retrospective 107 cohort study provides a unique real-world dataset for assessing the impact of combining KRAS 108 mutations with primary tumor size.

109

110 To summarize, primary tumor size is a key determinant of prognosis especially in the early 111 stages of NSCLC. At the same time, the prognostic value of *KRAS* mutational status in early 112 disease stages remains unclear. Hence patients diagnosed at an early stage are not

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

automatically tested for *KRAS* mutations and recommended treatment with *KRAS*-targeted therapy. Here, we investigate whether there is prognostic value in combining *KRAS* mutational

114 therapy. Here, we investigate whether there is prognostic value in combining ARAS initiational 115 status with tumor size to aid in clinical stratification of potentially treatment-responsive 116 subgroups in early-stage NSCLC.

117

118119 Materials and Methods

120

121 **Patient population**

We conducted a multi-center retrospective study including all consecutive NSCLC patients diagnosed with stage I-II NSCLC and molecular assessment performed between 2016-2018 in Västra Götaland, Sweden (n = 310). Further inclusion criteria included the availability of tumor size from CT scanning or a pathology report as well as follow-up data. Patients were excluded if diagnosed before 2016, had no digitally accessible patient charts, no tumor measurements noted in the patient charts, or had recurrent disease.

128

129 Patient demographics (age, sex, Eastern Cooperative Oncology Group [ECOG] performance 130 status [PS], and smoking history), cancer stage, pathological details (histology, mutational 131 status including KRAS mutational status and subtype), first-line treatment and outcome data 132 were retrospectively collected from patient charts and the Swedish Lung Cancer Registry. Clinical staging was based on TNM staging guidelines 7th edition [4]. TNM staging 8th edition 133 134 released in 2017 was introduced in Swedish guidelines in 2018, and full implementation was 135 reached in 2019. Ethical approval was obtained from the Swedish Ethical Review Authority 136 prior to study commencement (Dnr 2019-04771 and 2021-04987). No informed consent was 137 required due to all data presented in a de-identified form according to the Swedish Ethical 138 Review Authority.

139

140 *Mutational status*

Patients were assessed with next-generation sequencing (NGS) for mutational status on DNA from formalin-fixed paraffin-embedded (FFPE) blocks or cytological smears using the Ion AmpliSeq[™] Colon and Lung Cancer Panel v2 from Thermo Fisher Scientific as part of the

- diagnostic workup process at the Department of Clinical Pathology at Sahlgrenska University
 Hospital, assessing hotspot mutations in *EGFR*, *BRAF*, *KRAS*, and *NRAS*. Until June 2017,
- ALK-fusions were assessed with immunohistochemistry (IHC), and with fluorescence in situ
- 147 hybridization (FISH) if positive or inconclusive IHC. *ROS1* was analyzed upon request with

148 FISH. Thereafter, *ALK, ROS1,* and *RET* fusions were assessed on RNA using the Oncomine

- 149 Solid Tumor Fusion Panel from Thermo Fisher Scientific.
- 150

151 Tumor size

To obtain the most recent and accurate untreated primary tumor size, measurements were collected from the radiology report of computed tomography (CT) performed before a final diagnosis of NSCLC was established; this is referred as clinical staging. In patients who underwent surgical resection, the actual primary tumor size was also collected from the pathology report, also referred as pathological staging (PAD). The largest tumor diameter was

- 157 collected and reported in millimeters.
- 158

159 Study objectives

The primary outcome of this study was OS and risk of death, defined as the interval between the date of first treatment and the date of death from any cause. Patients alive or lost to followup at the cut-off date were censored at last contact. Median follow-up time was estimated using the reverse Kaplan-Meier method. We compared OS and risk of death stratified by *KRAS* mutational status, i.e., with no mutation in *KRAS* (wildtype, *KRAS*^{WT}), all *KRAS* mutations (*KRAS*^{MUT}), *KRAS G12C* mutations (*KRAS*^{MUT G12C}) and all *KRAS* mutations other than *G12C* (*KRAS*^{MUT not G12C}).

- 167
- 168 169
- 4

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

170 Statistical analysis

171 Clinical characteristics were summarized using descriptive statistics and evaluated with 172 univariate analysis in table form. Survival was estimated using the Kaplan-Meier method. The log-rank test was used to assess significant differences in OS between KRAS^{WT} and KRAS^{MUT} 173 groups. To evaluate if there was a significant difference in primary tumor size between 174 KRAS^{MUT} and KRAS^{WT}, the Mann-Whitney U test was used. Cox proportional hazard 175 176 regression was conducted to measure the influence of tumor size on the risk of death (hazard 177 ratio [HR]) stratified by KRAS mutational status. We defined an interaction term between tumor 178 size (largest diameter in mm) and KRAS mutational status to assess the combined impact on 179 the risk of death (HR). Statistical significance was set at p < 0.05 and no adjustments were 180 made for multiple comparisons. Data analysis was conducted using IBM SPSS Statistics 181 version 27 and GraphPad Prism version 9. 182

183 Results

184

185 Patients and tumor characteristics

186 A total of 310 consecutive patients, who were diagnosed with stage I-II NSCLC during 2016-187 2018 in Västra Götaland, Sweden and for whom genetic data was available, were included in 188 this retrospective cohort study (Fig. 1). In the total population, majority of patients were female 189 (187, 60.3%), with a median age of 70 years, and most were current or former smokers (267, 190 86%) (Table 1). Most patients had good PS with ECOG 0-1 at diagnosis (285, 92%) and the 191 proportion of N1 was low (18, 5.8%). NSCLC was predominantly adenocarcinoma of the lung 192 (281, 90.6%), while squamous cell carcinoma incidence was relatively low (11, 3.5%), which 193 was expected due to the selection of histological type for NGS assessment. Of included 194 patients, over a third (115, 37%) had a KRAS mutation (Table 1). This percentage matches 195 what has been previously reported [9], showing good representativeness of the patient group studied here. When comparing the baseline characteristics of KRAS^{WT} with KRAS^{MUT} patients, 196 a greater proportion of those with KRAS^{MUT} were female and current or former smokers. There 197 198 were no cases of squamous cell carcinoma in the *KRAS^{MUT}* group. The most common KRAS 199 mutation was G12C (47%). In the total population, majority of patients underwent surgical 200 resection (273, 88%; Table 2). Three patients did not receive any treatment and were excluded 201 from further survival analyses. Median follow-up time was 63 months (95% CI, 59.7-68.3) and 202 the data cut-off date was 31 October 2022.

203 204

205 No significant difference in survival for all patients stratified by *KRAS* mutations

When comparing OS for all (stage I-II) patients stratified by *KRAS* mutational status, no significant difference was detected with a mean OS (median not reached) of 74 months for *KRAS*^{WT} vs 63 months for *KRAS*^{MUT} (p = 0.847; Fig 2A). Further stratification of the *KRAS* mutated group by the G12C mutation also did not significantly change survival: 74 months for *KRAS*^{WT}, 61 months for *KRAS*^{MUT not G12C} and 63 months for *KRAS*^{MUT G12C} (p = 0.834; Fig 2D).

212

No significant difference in survival for patients in Stage I or Stage II disease combined with *KRAS* mutations

There were also no significant differences according to *KRAS* mutational status in stage I (Fig 2B, 2E) or Stage II (Fig 2C, 2F). Similarly in resected patients, no significant difference was observed with a mean OS (median not reached) of 78 months for *KRAS*^{WT} vs 65 months for *KRAS*^{MUT} (p = 0.856; Supplemental Fig. 1A), or between the subgroups of *KRAS*^{MUT} (p = 0.471; Supplemental Fig.1B).

220

Next, we stratified by stage and found mean OS (median not reached) of 79 months for stage I vs 50 months for stage II (Fig. S2A). We then conducted the analysis separately according to *KRAS* mutational status. For *KRAS*^{WT}, the mean OS (median not reached) was 78 months for stage I vs 46 months for stage II (Fig. S2B), and for *KRAS*^{MUT}, 65 months for stage I vs 53 months for stage II (Fig. S2C).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

227

No significant difference in survival for patients with TNM-stage T1, T2 or T3 disease combined with *KRAS* mutations

230 Next, we stratified patients using T-staging and studied OS according to KRAS mutational status. Among those with T1 disease, KRAS^{WT} had 83 months while KRAS^{MUT} had 66 months 231 OS (p = 0.751; Fig 3A). Further, KRAS^{MUT not G12C} patients had survival of 70 months and 232 KRAS^{MUT G12C} had 61 months (p = 0.344; Fig 3D). In the T2 group, KRAS^{WT} had 53 months 233 while *KRAS*^{MUT} had 59 months OS (*p* = 0.495; Fig 3B). *KRAS*^{MUT not G12C} patients had survival 234 of 51 months and KRAS^{MUT G12C} had 66 months (p = 0.389; Fig 3E). Similarly, in the T3 group, 235 KRAS^{WT} had 47 months while KRAS^{MUT} had 50 months OS (p = 0.966; Fig 3C). KRAS^{MUT not} 236 ^{G12C} patients had survival of 50 months and *KRAS*^{MUT G12C} had 53 months (p = 0.984; Fig 3F). 237 238

We further analyzed the impact of T stage on survival and found that it correlated as expected with mean OS of 82 months for T1, 55 months for T2, and 46 months for T3 (p < 0.001; Fig. S3A). The same trend was observed when separately analyzing *KRAS*^{WT} with a mean OS (median not reached) of 83 months for T1, 53 months for T2, and 45 months for T2 (p < 0.001; Fig. S3B), and *KRAS*^{MUT} with a mean OS of 65 months for T1, 58 months for T2, and 48 months for T3 (p < 0.023; Fig. S3C).

245 246

KRAS mutations are associated with smaller tumor size measured from CT scans, but not resection specimens/PAD

To evaluate differences between primary tumor size from CT scans at diagnosis stratified by *KRAS* mutational status, we used the Mann-Whitney U test. The test revealed that *KRAS*^{MUT} primary tumors were significantly smaller at diagnosis, with a median size of 20 mm (n = 115) vs *KRAS*^{WT} primary tumors with a median size of 25 mm (n = 190) (p = 0.043; Fig. 4A). However, when looking at tumor size as assessed in resected specimens, there were no differences; *KRAS*^{WT} median size 22 mm (n = 171) vs *KRAS*^{MUT} median size 21 mm (n = 102) (p = 0.16; Fig. 4B).

256 257

Larger tumor size measured from resection specimens/PAD, but not CT scans, is associated with a higher risk of death

We found that increase in primary tumor size determined from CT scans did not have a significant effect on risk of death (HR, 1.006; 95% CI, 0.922-1.021; p > 0.5) (Fig 4C). However, when testing the correlation between primary tumor size as assessed in resection specimens, we found a significantly increased risk of death (HR, 1.029; 95% CI, 1.012-1.046; p < 0.001) (Fig 4D). The risk of death increases with 2.9% for every mm increase of size.

266The combination of KRAS mutational status and tumor size does not impact the risk of267death

To test if the combination of tumor size and *KRAS* mutational status impacts the risk of death, we defined an interaction term including both variables. For primary tumor size from CT scans and *KRAS* mutational status, no significant difference in the risk of death was detected (HR, 1.008; 95% CI, 0.988-1.030; p > 0.5) (Fig 4C). Similarly, there were no significant differences for primary tumor size and *KRAS* mutational status when measured in resection specimens (HR, 1.002; 95% CI, 0.978-1.027; p = 0.807) (Fig 4D).

274 275

276 Discussion277

In this study, we assessed the prognostic value of combining *KRAS* mutational status with
 tumor size in early-stage NSCLC. We found that combining these variables had no significant
 effect on overall survival or the risk of death.

- 281
- 282 In alignment with previous findings, we found in our patient cohort that later disease stage and
- 283 larger primary tumor size is associated with worse survival. Interestingly, we found that these
 - 6

medRxiv preprint doi: https://doi.org/10.1101/2023.05.02.23289316; this version posted March 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

284 correlations are sustained independent of KRAS mutational status. Importantly, the 285 established literature on how KRAS mutations affect outcomes in early-stage NSCLC is 286 varying between worse survival and no significant difference. Here, we find as the latter, that 287 KRAS mutational status alone does not significantly impact OS or risk of death in patients with 288 stage I-II NSCLC. Patients harboring a KRAS G12C mutation did not have a worse OS. Taken 289 together, these findings show good representativeness of this well-defined patient cohort.

290

291 Our study included only patients with stage I-II disease due to the focus on primary tumor size 292 and to limit the prognostic impact of local invasion and regional lymph node involvement. Only 293 5.8% of the patients had N1 disease that could affect the prognosis. The major portion of the 294 patients had tumor resection and more than 90% of tumors were adenocarcinoma. During this 295 period, patients diagnosed with squamous cell carcinoma were molecularly assessed to a 296 lesser extent, thus our study is more representative of adenocarcinoma. Even though most 297 tumors were classified according the TNM staging guidelines 7th edition, changes included in 298 the 8th edition, mainly covering substages that were not analyzed in this study, do not alter our 299 findings [4].

300

301 When combining tumor size and KRAS mutational status there was no increased risk of death. 302 No significant differences were observed when comparing OS for all stage I-II patients 303 stratified by KRAS mutational status. However, the mean OS was 11 months shorter for KRAS^{MUT} patients. The same trend was observed when looking at resected patients with a 13-304 month shorter mean survival for KRAS^{MUT} patients. In this case, our results could differ from 305 306 former studies due to earlier studies not being corrected for tumor size [15, 16]. Our cohort 307 could be used as a historical reference if, in the future, sotorasib would be approved for 308 adjuvant treatment for patients harboring KRAS G12C mutation.

309

310 Outcome variables other than survival such as recurrence rates and progression-free survival 311 were not examined here. In addition, there remain confounders that were not include in the 312 analyses such as the effect of different treatment methods on survival. Further, we use the T 313 descriptor of the TNM staging system for tumor size even though the descriptor also includes 314 invasion status and or intrapulmonary metastasis. We found that larger tumor size measured 315 from resection specimens, but not CT scans, is associated with a higher risk of death. 316 However, one confounder here is that non-resected patients are included in the CT group but 317 not in the PAD group, which biases towards worse prognosis.

318

319 Going forward, much remains to be explored on the role of KRAS mutation in early NSCLC. 320 In the age of precision medicine, our study contributes towards the detailed level clinical data 321 that is required for future pooled analysis of prognosis assessments that can help guide clinical 322 decisions.

323

324 In conclusion, we confirm the importance of primary tumor size and stage as a prognostic 325 factor for survival in stage I-II NSCLC. KRAS mutations were not found to impact OS and no 326 difference in the risk of death was observed when combining KRAS mutations and primary 327 tumor size.

- 328
- 329
- 330

331 **Declarations**

332 **Acknowledgments**

333 We thank Sayin lab members and Nesrin Vurgun, Scientific editor at the Institute of Clinical 334 Sciences, University of Gothenburg for a critical review of the manuscript. In addition, we thank 335 members of the Swedish Lung Cancer Registry and the continuous reporting by Swedish 336 healthcare employees.

- 337 338 **Authors' contributions**
- 339 Conceptualization, E.A.E., H.F., A.H. and V.I.S.; Data curation, E.A.E., A.M., H.F.; Formal 340 analysis, E.A.E., A.M. and C.W.; Funding acquisition, E.A.E., C.W., H.F., A.H. and V.I.S.;
 - 7

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

341 Methodology, E.A.E.; Resources, H.F.; Supervision, A.H. and V.I.S.; Visualization, E.A.E.,

- 342 S.I.S., C.W. and V.I.S.; Writing-original draft, E.A.E., S.I.S and V.I.S.; Writing-review & 343 editing, E.A.E., S.I.S, C.W., H.F., A.H. and V.I.S., Project coordination, V.I.S. All authors have
- 344 read and agreed to the published version of the manuscript.
- 345

346 Funding

347 This work was supported by the Swedish Research Council (2018-02318 and 2022-00971 to 348 VIS, 2021-03138 to CW), the Swedish Cancer Society (23-3062 to VIS, 22-0612FE to CW), 349 the Gothenburg Society of Medicine (2019; 19/889991 to EAE), Assar Gabrielsson Research 350 Foundation (to EAE, CW, and VIS), the Swedish state under the agreement between the 351 Swedish government and the county councils, the ALF-agreement (to HF), Department of 352 Oncology, Sahlgrenska University Hospital (to EAE and AH), the Swedish Society for Medical 353 Research (2018; S18-034 to VIS), the Knut and Alice Wallenberg Foundation, and the 354 Wallenberg Centre for Molecular and Translational Medicine (to VIS).

355

356 **Declaration of potential conflict of interest**

357 The authors declare no conflicts of interest.

358

359 Institutional Review Board Statement

360 Approval from the Swedish Ethical Review Authority (Dnr 2019-04771 and 2021-04987) was 361 obtained prior to the commencement of the study. No informed consent was required due to 362 all data presented in a de-identified form according to the Swedish Ethical Review Authority.

363 364

365 **Consent for publication**

366 Not applicable. Patient consent statements were not required due to the retrospective nature 367 of this study. No informed consent was required due to all data presented in a de-identified 368 form according to the Swedish Ethical Review Authority.

369 370

371 **Data Availability Statement**

- 372 The datasets used and/or analysed during the current study available from the corresponding
- 373 author on reasonable request.
- 374

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

375 References 376 World Health Organization, International Agency for Research on Cancer. Globocan 2020: 1. 377 Lung Cancer. International Agency for Research on Cancer. Available at 378 http://qco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed: March 2, 379 2021. 380 2. Amin, M.B., et al., The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a 381 bridge from a population-based to a more "personalized" approach to cancer staging. CA 382 Cancer J Clin, 2017. 67(2): p. 93-99. 383 3. Detterbeck, F.C., The eighth edition TNM stage classification for lung cancer: What does it 384 mean on main street? J Thorac Cardiovasc Surg, 2018. 155(1): p. 356-359. 385 4. Goldstraw, P., et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the 386 TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung 387 Cancer. J Thorac Oncol, 2016. 11(1): p. 39-51. 388 Wankhede, D., Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A Meta-analysis. 5. 389 Ann Surg Oncol, 2021. 28(1): p. 142-147. 390 6. Tartarone, A., et al., Beyond Conventional: The New Horizon of Targeted Therapy for the 391 Treatment of Advanced Non Small Cell Lung Cancer. Front Oncol, 2021. 11: p. 632256. 392 7. Brady, A.K., et al., Survival outcome according to KRAS mutation status in newly diagnosed 393 patients with stage IV non-small cell lung cancer treated with platinum doublet 394 chemotherapy. Oncotarget, 2015. 6(30): p. 30287-94. 395 8. Eklund, E.A., et al., KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell 396 Lung Cancer. Cancers (Basel), 2022. 14(9). 397 9. Goulding, R.E., et al., KRAS mutation as a prognostic factor and predictive factor in 398 advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-399 analysis. Cancer Treat Res Commun, 2020. 24: p. 100200. 400 10. Hallqvist, A., et al., Mutated KRAS Is an Independent Negative Prognostic Factor for Survival 401 in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer Int, 2012. 402 **2012**: p. 587424. 403 11. Hames, M.L., et al., Correlation between KRAS mutation status and response to 404 *chemotherapy in patients with advanced non-small cell lung cancer* ★. Lung Cancer, 2016. 405 92: p. 29-34. 406 12. Marabese, M., et al., KRAS mutations affect prognosis of non-small-cell lung cancer patients 407 treated with first-line platinum containing chemotherapy. Oncotarget, 2015. 6(32): p. 34014-408 22. 409 13. Mellema, W.W., et al., KRAS mutations in advanced nonsquamous non-small-cell lung cancer 410 patients treated with first-line platinum-based chemotherapy have no predictive value. J 411 Thorac Oncol, 2013. 8(9): p. 1190-5. 412 14. Rodenhuis, S., et al., Mutational activation of the K-ras oncogene and the effect of 413 chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol, 414 1997. 15(1): p. 285-91. 415 15. Meng, D., et al., Prognostic value of K-RAS mutations in patients with non-small cell lung 416 cancer: a systematic review with meta-analysis. Lung Cancer, 2013. 81(1): p. 1-10. 417 16. Kadota, K., et al., KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung 418 Adenocarcinoma. Am J Surg Pathol, 2016. 40(12): p. 1579-1590. 419 17. Izar, B., et al., The prognostic impact of KRAS, its codon and amino acid specific mutations, on 420 survival in resected stage I lung adenocarcinoma. J Thorac Oncol, 2014. 9(9): p. 1363-9. 421 18. D'Angelo, S.P., et al., Distinct clinical course of EGFR-mutant resected lung cancers: results of 422 testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. Journal of 423 Thoracic Oncology, 2012. 7(12): p. 1815-1822 %@ 1556-0864. 424 19. Gallina, F.T., et al., KRAS G12C mutation and risk of disease recurrence in stage I surgically 425 resected lung adenocarcinoma. Lung Cancer, 2023. 181: p. 107254. 426 20. Ihle, N.T., et al., Effect of KRAS oncogene substitutions on protein behavior: implications for 427 signaling and clinical outcome. J Natl Cancer Inst, 2012. 104(3): p. 228-39.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.02.23289316; this version posted March 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

428 429	21.	Garinet, S., et al., <i>Updated Prognostic Factors in Localized NSCLC</i> . Cancers (Basel), 2022. 14 (6).
430	22.	Remon, J., J.C. Soria, and S. Peters, Early and locally advanced non-small-cell lung cancer: An
431 432		update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Annals of Oncology, 2021. 32 (12): p. 1637-1642 %@ 0923-7534.
433	23.	Addeo, A., G.L. Banna, and A. Friedlaender, KRAS G12C Mutations in NSCLC: From Target to
434		Resistance. Cancers (Basel), 2021. 13(11).
435	24.	Burns, T.F., et al., Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a
436		<i>Time, With a Focus on KRAS G12C Mutations.</i> J Clin Oncol, 2020. 38 (35): p. 4208-4218.
437	25.	Indini, A., et al., Targeting KRAS in Solid Tumors: Current Challenges and Future
438		Opportunities of Novel KRAS Inhibitors. Pharmaceutics, 2021. 13(5).
439 440	26.	Mathieu, M., et al., <i>KRAS G12C fragment screening renders new binding pockets</i> . Small GTPases, 2021: p. 1-14.
441	27.	Skoulidis, F., et al., Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med,
442		2021.
443	28.	Chen, Y., et al., Prognostic factors of survival in patients with non-small cell lung cancer: a
444		competing risk model using the SEER database. Transl Cancer Res, 2022. 11(11): p. 3974-
445		3985.
446	29.	Gerber, D.E., et al., Baseline tumour measurements predict survival in advanced non-small
447		<i>cell lung cancer.</i> Br J Cancer, 2013. 109 (6): p. 1476-81.
448	30.	Okada, M., et al., Effect of tumor size on prognosis in patients with non-small cell lung
449		cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg,
450		2005. 129 (1): p. 87-93.
451	31.	Zhang, J., et al., Relationship between tumor size and survival in non-small-cell lung cancer
452		(NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J
453		Thorac Oncol, 2015. 10 (4): p. 682-90.
454	32.	Goldie, J.H. and A.J. Coldman, A mathematic model for relating the drug sensitivity of tumors
455		to their spontaneous mutation rate. Cancer treatment reports, 1979. 63(11-12): p. 1727-
456		1733.
457	33.	Skipper, H.E., Thoughts on Cancer Chemotherapy and Combination Modality Therapy
458		<i>(1974).</i> JAMA, 1974. 230 (7): p. 1033-1035.
459	34.	Jain, R.K., Physiological Barriers to Delivery of Monoclonal Antibodies and Other
460		Macromolecules in Tumors1. Cancer Research, 1990. 50(3_Supplement): p. 814s-819s.
461	35.	Trédan, O., et al., Drug Resistance and the Solid Tumor Microenvironment. JNCI: Journal of
462		the National Cancer Institute, 2007. 99 (19): p. 1441-1454.
463		
464		

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

465 **Figure legends**

- 466
- 467 **Table 1** Characteristics of the total cohort as well as stratified by $KRAS^{WT}$ and $KRAS^{MUT}$. Data 468 are presented as n (%).
- 469 ECOG PS, Eastern Cooperative Oncology Group Performance Status. T, Tumor. N, Nodulus. 470
- 471 **Table 2** Summary of first-line treatments in the total cohort as well as stratified by $KRAS^{WT}$ 472 and $KRAS^{MUT}$. Data are presented as n (%).
- 473

474 **Figure 1. Patient selection**

- 475 Flow chart showing patient selection for the study.
- 476

482

477 Figure 2. Impact of *KRAS* mutational status on overall survival in Stage I and II NSCLC.

- Kaplan-Meier estimates comparing overall survival between (A, D) all patients, (B, E) Stage I
 and (C, F) Stage II patients with no mutation in *KRAS* (wildtype, *KRAS*^{WT}), with all *KRAS*mutations (*KRAS*^{MUT}), only *KRAS-G12C* mutations (*KRAS*^{MUT G12C}) and *KRAS* mutations other
 than *G12C* (*KRAS*^{MUT not G12C}).
- Figure 3. Impact of *KRAS* mutational status on overall survival across TNM-stages in
 NSCLC
- 485 Kaplan-Meier estimates comparing overall survival between (**A**, **D**) T1, (**B**, **E**) T2 and (**C**, **F**) 486 T3 patients with no mutation in *KRAS* (wildtype, *KRAS*^{WT}), with all *KRAS* mutations 487 (*KRAS*^{MUT}), only *KRAS-G12C* mutations (*KRAS*^{MUT G12C}) and *KRAS* mutations other than 488 *G12C* (*KRAS*^{MUT not G12C}).
- 489

490 Figure 4. KRAS mutations are associated with smaller tumor size at diagnosis

- Primary tumor size from (**A**) CT scans and (**B**) resection specimens (PAD) in patients with no mutation in *KRAS* (wildtype, *KRAS*^{WT}) or with *KRAS* mutations (*KRAS*^{MUT}). Forest plot of multivariate COX regression analysis for patients with tumor size from (**C**) CT scan and (**D**) resection specimens (PAD).
- 495

496 Supplemental Figure 1

- Kaplan-Meier estimates of overall survival for resected Stage I-II NSCLC patients stratified by
 KRAS mutational status. (A) No mutation in *KRAS* (wildtype, *KRAS*^{WT}), with all *KRAS*mutations (*KRAS*^{MUT}). (B) Only *KRAS-G12C* mutations (*KRAS*^{MUT G12C}), *KRAS* mutations other
 than *G12C* (*KRAS*^{MUT not G12C}).
- 501
- 502

503 Supplemental Figure 2

- 504 Kaplan-Meier estimates comparing overall survival for (**A**) all patients, (**B**) patients with no 505 mutation in *KRAS* (wildtype, *KRAS*^{WT}), and (**C**) with all *KRAS* mutations (*KRAS*^{MUT}), stratified 506 by Stages I and II.
- 507

508 Supplemental Figure 3

509 Kaplan-Meier estimates comparing overall survival for (**A**) all patients, (**B**) patients with no 510 mutation in *KRAS* (wildtype, *KRAS*^{WT}), and (**C**) with all *KRAS* mutations (*KRAS*^{MUT}), stratified 511 by TNM-stages T1, T2 and T3.

- 512
- 513
- 514

medRxiv preprint doi: https://doi.org/10.1101/2023.05.02.23289316; this version posted March 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1.	Characteristics all	patients stage I-II NSCLC
----------	---------------------	---------------------------

	Total	KRAS WT	KRAS MUT
	n (%)	n (%)	n (%)
Total	310 (100)	105 (63 0)	115 (37 0)
Ago in yoars, modian (rango)	70 (35 85)	70 (35 85)	70 (48 84)
Age in years, median (range)	10 (33-63)	70 (33-63)	70 (40-04)
Mala	102 (20 7)	00 (15 1)	25 (20 4)
	123 (39.7)	00 (40.1) 407 (54.0)	35 (30.4)
	187 (60.3)	107 (54.9)	80 (69.6)
Smoking history	00 (01 0)	54 (00.0)	40 (44 7)
	99 (31.9)	51 (26.2)	48 (41.7)
Former smoker	168 (54.2)	106 (54.4)	62 (53.9)
Never smoker	43 (13.9)	38 (19.5)	5 (4.3)
Perfomance status			
ECOG 0	144 (46.5)	82 (42.1)	62 (53.9)
ECOG 1	141 (45.5)	96 (49.2)	45 (39.1)
ECOG 2	24 (7.7)	16 (8.2)	8 (7.0)
ECOG 3	1 (0.3)	1 (0.5)	0
ECOG 4	0	0	0
Histology			
Adenocarcinoma	281 (90.6)	168 (86.2)	113 (98.3)
Squamous cell carcinoma	11 (3.5)	11(5.6)	0
NCSLC NOS	18 (5.9)	16 (8.2)	2 (1.7)
Mutation status			
None known	124 (40.2)	124 (63.6)	
KRAS	115 (37.0)	0	
EGFR	54 (17.4)	54 (27.7)	
BRAF	6 (1.9)	6 (3.1)	
ALK	4 (1.3)	4 (2.1)	
ROS1	3 (1.0)	3 (1.5)	
RET	1 (0.3)	1 (0.5)	
Other	3 (1.0)	3 (1.5)	
KRAS submutation	- ()		
G12A			9 (7 8)
G12C			54 (47 0)
G12D			15 (13.0)
G12V			26 (22 6)
Other			11 (9.6)
TNM			11 (0.0)
 T1a	99 (31 9)	55 (28 2)	44 (38 3)
T1b	76 (24 5)	54 (27 7)	22 (19 1)
T1c	12 (3 9)	7 (3 6)	5(43)
T2a	67 (21 6)	46 (23 6)	21 (18.3)
T2b	28 (9 0)	40 (20.0) 15 (7 8)	13 (11 3)
T20 T3	28 (9.0)	18 (0.2)	10 (8 7)
NO	20 (0.0)	185 (0/ 0)	107 (03 0)
NU NI	292 (94.2) 18 (5.8)	105 (94.9)	8 (7 0)
Mossuroment medality	10 (0.0)	10 (3.1)	0(1.0)
	205 (09 4)	100 (07 4)	115 (100)
	303 (30.4) 272 (90 A)	190 (97.4) 171 (00 7)	110 (100) 100 (00 7)
FAU At lost follow up 21/10 2022	ZIS (00.U)	1/1 (00./)	102 (00.7)
At last IOIIOW UP 31/10-2022			70 (07 0)
			/ ୪ (୪/.୪)
	104 (33.5)	67 (34.4)	37 (32.2)
Survival			
Mean survival (months)	63	62	64

medRxiv preprint doi: https://doi.org/10.1101/2023.05.02.23289316; this version posted March 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Treatment table all patients stage I-II NSCLC

	Total	KRAS WT	KRAS MUT
	n (%)	n (%)	n (%)
Total	310 (100)	195 (63.0)	115 (37.0)
Surgery	273 (88.0)	171 (87.7)	102 (88.7)
Curative chemoradiotherapy	7 (2.3)	6 (3.1)	1 (0.9)
Medical treatment	2 (0.6)	1 (0.5)	1 (0.9)
Stereotactic radiotherapy	11 (3.5)	11 (5.6)	0 (0)
Radiotherapy	14 (4,5)	3 (1,5)	11 (9.6)
No treatment	3 (1.0)	3 (1.5)	0 (0)
		•	













medRxiv preprint doi: https://doi.org/10.1101/2023.05.02.23289316; this version posted March 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Eklund et al. Figure 3 It is made available under a CC-BY-NC-ND 4.0 International license .













medRxiv preprint doi: https://doi.org/10.1101/2023.05.02.23289316; this version posted March 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Eklund et al. Figure 4 It is made available under a CC-BY-NC-ND 4.0 International license .

